GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Valuation Rank

Benevolent AI (Benevolent AI) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Benevolent AI Valuation Rank Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Valuation Rank
Comparable Companies
Traded in Other Exchanges
BAI:Netherlands 2XA:Germany
Address
4-8 Maple Street, London, GBR, W1T 5HD
Website
https://www.benevolent.com
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.